Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: The evaluate study

Blood Pressure Monitoring

Volumn 14, Issue 3, 2009, Pages 112-120

  Lacourciere, Yves ^a   Wright Jr , Jackson T ^b   Samuel, Rita ^c   Zappe, Dion ^c   Purkayastha, Das ^c   Black, Henry R ^d  

^a LAVAL UNIVERSITY   (Canada)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ambulatory blood pressure. amlodipine. combination therapy. hydrochlorothiazide. hypertension. valsartan

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE; ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; UNCLASSIFIED DRUG; VALSARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; MONOTHERAPY; MULTICENTER STUDY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SITTING; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 67649820131     PISSN: 13595237     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBP.0b013e32832a9da7     Document Type: Article

References (22)

1. 1 White WB. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension. Blood Press Monit 2008; 13:123-129.
2. Chobanian AV. Bakris GL. Black HR. Cushman WC. Green LA. Izzo JL Jr. et al. Seventh report of the Joint National Committee on Prevention. Detection. Evaluation. and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
3. Mancia G. De Backer G. Dominiczak A. Cifkova R. Fagard R. Germano G. et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25:1751-1762.
4. Julius S. Kjeldsen SE. Weber M. Brunner HR. Ekman S. Hansson L. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031.
5. Kario K. Pickering T. Value: analysis of results. Lancet 2004; 364:934.
6. Lacourciere Y. Neutel JM. Schumacher H. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 and 80/12.5mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5mg in mild to moderate essential hypertension: pooled analysis of two multicenter. prospective. randomized. open-label. blinded-end point (PROBE) trials. Clin Ther 2005; 27:1795-1805.
7. Lacourciere Y. Poirier L Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension. AmJ Hypertens 2003; 16:1036-1042.
8. Lacourciere Y. Poirier L. Hebert D. Assouline L. Stolt P. Rehel B. et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week. randomized. double-blind. parallel-group trial. Clin Ther 2005; 27:1013-1021.
9. Oparil S. Abate N. Chen E. Creager MA. Galet V. Jia G. et al. A double-blind. randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension. Curr Med Res Opin 2008; 24:1101-1114.
10. Pool JL. Glazer R. Weinberger M. Alvarado R. Huang J. Graff A. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind. placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007; 29:61-73.
11. Ruilope LM. Malacco E. Khder Y. Kandra A. Bonner G. Heintz D. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 2005; 27:578-587.
12. Weber MA. White WB. Giles TD. Bakris GL. Neutel JM. Smith DH. et al. An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements. J Clin Hypertens (Greenwich) 2006; 8:241-250; quiz 251-242.
13. Weir MR. Ferdinand KC. Flack JM. Jamerson KA. Daley W. Zelenkofske S. A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. Hypertension 2005; 46:508-513.
14. Ohkubo T. Imai Y. Tsuji I. Nagai K. Kato J. Kikuchi N. et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama. Japan. J Hypertens 1998; 16:971-975.
15. Staessen JA. Thijs L. Fagard R. O'Brien ET. Clement D. de Leeuw PW. et al. Predicting cardiovascular risk using conventional vs. ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999; 282:539-546.
16. Dolan E. Stanton A. Thijs L. Hinedi K. Atkins N. McClory S. et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005; 46:156-161.
17. Graettinger WF. Lipson JL. Cheung DG. Weber MA. Validation of portable noninvasive blood pressure monitoring devices: comparisons with intra-arterial and sphygmomanometer measurements. Am Heart J 1988; 116:1155-1160.
18. Mallion JM. Carretta R. Trenkwalder P. Martinez JF.Tykarski A. Teitelbaum I. et al. Valsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press Suppl 2003; 1:36-43.
19. White WB. Clinical relevance of ambulatory versus clinic blood pressure when evaluating antihypertensive therapy. Stood Press Monit 1996; 1:170-173.
20. McGrath BP. Ambulatory blood pressure monitoring. Med J Aust 2002; 176:588-592.
21. O'Brien E. Coats A. Owens P. Petrie J. Padfield PL. Littler WA. etal. Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British hypertension society. BMJ 2000; 320:1128-1134.
22. Myers MG. Haynes RB. Rabkin SW. Canadian hypertension society guidelines for ambulatory blood pressure monitoring. Am J Hypertens 1999; 12:1149-1157.